Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.
Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.
复制标题
DOI:
10.1007/s11912-020-0888-x
复制
发表时间:
2020-02-12
影响因子:
4.7
通讯作者:
Matsuo K
中科院分区:
文献类型:
--
作者:
Matsuzaki S;Klar M;Mikami M;Shimada M;Grubbs BH;Fujiwara K;Roman LD;Matsuo K
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer. Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (N = 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer. Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.
登录
查看更多内容
影响因子:
8.4
作者:
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者:
Verweij, J.
影响因子:
8.8
作者:
通讯作者:
--
影响因子:
3.5
作者:
Cibula, David;Poetter, Richard;Raspollini, Maria Rosaria
通讯作者:
Raspollini, Maria Rosaria
影响因子:
3.8
作者:
Chai Y;Wang T;Wang J;Yang Y;Gao Y;Gao J;Gao S;Wang Y;Zhou X;Liu Z
通讯作者:
Liu Z
影响因子:
4.7
作者:
Chen, Huijun;Liang, Chuan;Wu, Xufeng
通讯作者:
Wu, Xufeng